Pott Christian, Steinritz Dirk, Napp Andreas, Bloch Wilhelm, Schwinger Robert H G, Brixius Klara
Universitätsklinikum Münster, Medizinische Klinik und Poliklinik C für Kardiologie und Angiologie, Münster, Germany.
Wien Med Wochenschr. 2006 Aug;156(15-16):451-8. doi: 10.1007/s10354-006-0273-x.
Beta-adrenergic stimulation is an important regulatory mechanism of cardiac function. Next to beta1- and beta2-adrenoceptors, the expression of a third beta-adrenoceptor population, the beta3-adrenoceptor, has recently been evidenced in the human heart. Stimulation of cardiac beta3-adrenoceptors leads to a decrease in contractility via a release of nitric oxide (NO). In this context, different molecular mechanisms of endothelial nitric oxide synthase (eNOS) activation have been uncovered to occur as a consequence of beta3-adrenergic stimulation. In both nonfailing and failing myocardium, beta3-adrenergic stimulation may have a protective effect against excessive chatecolaminergic stimulation as it occurs during somatic and mental stress and during heart failure. For this reason, the beta3-adrenoceptor is discussed as a possible target for the pharmacological therapy of heart failure.
β-肾上腺素能刺激是心脏功能的重要调节机制。除了β1和β2肾上腺素能受体外,最近在人类心脏中证实了第三种β-肾上腺素能受体群体β3-肾上腺素能受体的表达。刺激心脏β3-肾上腺素能受体会通过释放一氧化氮(NO)导致收缩力下降。在这种情况下,已经发现β3-肾上腺素能刺激会引发内皮型一氧化氮合酶(eNOS)激活的不同分子机制。在非衰竭和衰竭心肌中,β3-肾上腺素能刺激可能对过度的儿茶酚胺能刺激具有保护作用,如在躯体和精神应激以及心力衰竭期间发生的那样。因此,β3-肾上腺素能受体被认为是心力衰竭药物治疗的一个可能靶点。